secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001213900-26-051125
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds settles merger dispute; Lokahi provides $4M working capital; board to transition
--------------------------------------------------------------------------------

- Settlement resolves all disputes from Dec 2025 Merger Agreement; Lokahi retains Apitox program assets valued at ~$2.2M.
- Lokahi provides $4M working capital to Company and forgives $750k advance; 51% of Lokahi stock to be distributed to Emerson.
- Newco formed as wholly owned subsidiary, to be spun off within 12 months; 10% of net financing proceeds allocated to Newco.
- Board changes: Stockholder Consents voided; Koo to resign; interim board of three; then three new independent directors appointed by Inscobee.
- Forbearance Agreement with Alto Opportunity Master Fund extends forbearance on $11M note defaults through June 30, 2026, subject to conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026051125/0001213900-26-051125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026051125/ea0288393-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-051125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer